Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4606 Neuroendocrine mess – Ectopic Cushing syndrome and severe hypokalaemia

Introduction: Cushing Syndrome (CS) is the condition resulting from hypercortisolaemia. Ectopic Cushing Syndrome (ECS) is responsible for up to 20% of all CS cases. Pancreatic neuroendocrine neoplasms (pNEN) are responsible for 10-20% of those cases.

Conference:

Presenting Author:

Authors: Corrêa Figueira C, Alves H, Bento A, Cardoso Gomes C, Oliveira A,

Keywords: Pancreatic neuroendocrine neoplasm, Hepatic neuroendocrine metastasis, Paraneoplastic syndrome, Cushing syndrome, Ectopic Cushing syndrome,

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,